American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

MetaVia Inc. (MTVA)

$1.38 -0.72% NASDAQ: MTVA · 15-min delayed

CAMBRIDGE, Massachusetts
Public · NASDAQ: MTVA
8 employees

Visit website Follow

$7.6MMarket cap

-$13.0MNet income

8Employees

MTVANASDAQ

2016IPO

About MetaVia Inc.

MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: MTVA
Employees: 8
IPO date: Aug 4, 2016
Headquarters: 545 CONCORD AVENUE
CAMBRIDGE, Massachusetts 02138
Phone: (857) 702-9600
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: MTVA Nasdaq
SEC CIK: 1638287
EIN: 472389984
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show MetaVia Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/metavia-inc/"><img src="https://americancompanies.com/badge/metavia-inc.svg" alt="MetaVia Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow MetaVia Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Net income: -$13.0M
Total assets: $11.1M
Market cap: $7.6M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: MTVA

$1.38 -0.72%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.97 $11.99

52-week range

Market cap: $7.6M
Shares outstanding: 5.5M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Aug 4, 2016

MetaVia Inc. (MTVA) Stock Price

Reported a net loss of $13.0M.
Trading 88% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review MetaVia Inc..

Write a review

Newsroom

News about MetaVia Inc.

Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight GlobeNewswire Inc. · 2026-10-21 · positive Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing GlobeNewswire Inc. · 2026-06-26 · neutral

News & sentiment via Polygon.io

FAQ

MetaVia Inc.: frequently asked questions

Is MetaVia Inc. an American company?

MetaVia Inc. is a US-based company headquartered in Cambridge, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is MetaVia Inc. headquartered?

MetaVia Inc. is headquartered in Cambridge, Massachusetts, United States.

Is MetaVia Inc. publicly traded?

Yes — MetaVia Inc. is a publicly traded company. Its stock trades under the ticker symbol MTVA on the NASDAQ.

What does MetaVia Inc. do?

MetaVia Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore